In 2010, Governor Deval Patrick directed the Executive Office of Elder Affairs, in partnership with the Alzheimer’s Association Massachusetts/New Hampshire Chapter, to draft a state plan addressing Alzheimer’s disease within the state. In response, these two agencies convened an Advisory Committee that included families and individuals impacted by the disease as well as representatives from state and local health and human services agencies, councils on aging, academia, public safety agencies, and professional caregiver associations. Gathering public input, the Advisory Committee published the Massachusetts Alzheimer’s Disease and Related Disorders State Plan in February 2012. Following 2018 legislation (Chapter 220 of the Acts of 2018), a new State Alzheimer’s Plan was released in April 2021.

Improve Access to Biomarker Testing 

With the historic Food and Drug Administration (FDA) approval of treatments that slow the progression of Alzheimer’s in the early stages, early detection and diagnosis are even more critical to ensure individuals receive the most benefit at the earliest point possible. Biomarkers offer one of the most promising paths to improve dementia detection, diagnosis and treatment. Yet these critical tests remain out of reach for many as insurance coverage is failing to keep pace with innovations and advancements in treatments. The Alzheimer’s Association is urging state lawmakers to expand insurance coverage of comprehensive biomarker testing. Without this legislation, dementia diagnoses may take up to two years, increasing the long-term costs to the individual, family and the state.